CRO ProSciento, OWL Metabolomics growing patient database

By Melissa Fassbender contact

- Last updated on GMT

ProSciento has a proprietary site database of more than 30,000 active study participants. (Image: iStock/MickeyCZ)
ProSciento has a proprietary site database of more than 30,000 active study participants. (Image: iStock/MickeyCZ)

Related tags: Clinical research

ProSciento and OWL Metabolomics have formed a strategic collaboration to accelerate NAFLD/NASH clinical trial recruitment.

ProSciento – previously the Profil Institute for Clinical Research – is a full scope clinical R&D provider that focuses on diabetes, obesity, and NAFLD/NASH.

OWL Metabolomics is a biotechnology company that develops virtual biopsy assays, including ‘OWLiver’ and ‘OWLiver Care’ assays, which are metabolomics-based in-vitro tests for diagnosing non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Speaking on the partnership’s formation, Christian Weyer, MD, ProSciento’s president and chief development officer, told Outsourcing-Pharma.com “it became clear that one of the big unmet needs was in finding patients to enroll in [NAFLD/NASH] clinical trials​.”

There was an important opportunity to join forces in enhancing and improving how we can identify subjects that would be available for trials​,” he added.

The partnership is a multiyear collaboration, though no other details on length are being released at this time. However, Weyer explained, “Certainly, we see a lot of opportunity here​.”

Per the agreement, the companies will co-create a clinical study participant database of prospective patients evaluated for the presence of NAFLD and NASH using OWL’s non-invasive, lipidomics-based diagnostic assays.

Weyer explained the plan is to launch at ProSciento’s early phase clinical research unit before expanding over time into its network of other study sites.

We already have a subject database of about 30,000 active study participants at our clinical research unit​,” he explained. “On top of that, we have a sizeable database of subjects as part of our networks of sites that we can tap into​.”

Additionally, OWL is joining ProSciento’s CRI (Clinical Research Innovation) partner network, which includes corporate and academic firms that offer “clinical research methodologies​” to support and accelerate metabolic drug and device development, the company explained.

At ProSciento we have the ability to connect clients with novel technologies​,” said Weyer. “We partner with a network of companies and academic collaborators to provide clients with access to those technologies. I think the OWL partnership is a very good example of that network approach​.”

Related news

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars